JPWO2022051437A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022051437A5 JPWO2022051437A5 JP2023514418A JP2023514418A JPWO2022051437A5 JP WO2022051437 A5 JPWO2022051437 A5 JP WO2022051437A5 JP 2023514418 A JP2023514418 A JP 2023514418A JP 2023514418 A JP2023514418 A JP 2023514418A JP WO2022051437 A5 JPWO2022051437 A5 JP WO2022051437A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cells
- fragment
- composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 381
- 102000004169 proteins and genes Human genes 0.000 claims description 256
- 108090000623 proteins and genes Proteins 0.000 claims description 256
- 102000004127 Cytokines Human genes 0.000 claims description 193
- 108090000695 Cytokines Proteins 0.000 claims description 193
- 239000000203 mixture Substances 0.000 claims description 191
- 239000000427 antigen Substances 0.000 claims description 165
- 102000036639 antigens Human genes 0.000 claims description 165
- 108091007433 antigens Proteins 0.000 claims description 165
- 108020004999 messenger RNA Proteins 0.000 claims description 156
- 238000000034 method Methods 0.000 claims description 156
- 239000012634 fragment Substances 0.000 claims description 152
- 210000002865 immune cell Anatomy 0.000 claims description 148
- 239000012528 membrane Substances 0.000 claims description 110
- 150000007523 nucleic acids Chemical group 0.000 claims description 92
- 108020004707 nucleic acids Proteins 0.000 claims description 88
- 102000039446 nucleic acids Human genes 0.000 claims description 88
- 239000006285 cell suspension Substances 0.000 claims description 85
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 77
- 230000000139 costimulatory effect Effects 0.000 claims description 63
- 239000002671 adjuvant Substances 0.000 claims description 39
- 230000001143 conditioned effect Effects 0.000 claims description 34
- 230000028993 immune response Effects 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 230000008685 targeting Effects 0.000 claims description 32
- 241000701806 Human papillomavirus Species 0.000 claims description 30
- 239000000725 suspension Substances 0.000 claims description 30
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 22
- 239000000556 agonist Substances 0.000 claims description 20
- 108020001507 fusion proteins Proteins 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 18
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 16
- 241000700721 Hepatitis B virus Species 0.000 claims description 16
- 230000004936 stimulating effect Effects 0.000 claims description 16
- 108010047761 Interferon-alpha Proteins 0.000 claims description 15
- 102000006992 Interferon-alpha Human genes 0.000 claims description 15
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 210000004443 dendritic cell Anatomy 0.000 claims description 14
- 102000054766 genetic haplotypes Human genes 0.000 claims description 14
- 210000001616 monocyte Anatomy 0.000 claims description 14
- 210000000822 natural killer cell Anatomy 0.000 claims description 14
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 10
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 10
- 102100037850 Interferon gamma Human genes 0.000 claims description 10
- 108010074328 Interferon-gamma Proteins 0.000 claims description 10
- 229940044606 RIG-I agonist Drugs 0.000 claims description 10
- 229940044665 STING agonist Drugs 0.000 claims description 10
- 229940124614 TLR 8 agonist Drugs 0.000 claims description 10
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 10
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 10
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 10
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 10
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 8
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 8
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 8
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 8
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 8
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 8
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 8
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 7
- 101710132601 Capsid protein Proteins 0.000 claims description 7
- 108010058643 Fungal Proteins Proteins 0.000 claims description 7
- 102100026720 Interferon beta Human genes 0.000 claims description 7
- 108090000467 Interferon-beta Proteins 0.000 claims description 7
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- 102000008300 Mutant Proteins Human genes 0.000 claims description 7
- 108010021466 Mutant Proteins Proteins 0.000 claims description 7
- 108700020796 Oncogene Proteins 0.000 claims description 7
- 102000043276 Oncogene Human genes 0.000 claims description 7
- 108010067390 Viral Proteins Proteins 0.000 claims description 7
- 102100034980 ICOS ligand Human genes 0.000 claims description 6
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 108010074108 interleukin-21 Proteins 0.000 claims description 5
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100036008 CD48 antigen Human genes 0.000 claims description 4
- 102100025221 CD70 antigen Human genes 0.000 claims description 4
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 4
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 4
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims description 4
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims description 4
- 101710093458 ICOS ligand Proteins 0.000 claims description 4
- -1 LIGHT Proteins 0.000 claims description 4
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 4
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims description 4
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 4
- 102100035488 Nectin-2 Human genes 0.000 claims description 4
- 108010042215 OX40 Ligand Proteins 0.000 claims description 4
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 4
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims description 4
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 4
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 4
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 4
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 4
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 4
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 108010048507 poliovirus receptor Proteins 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000709721 Hepatovirus A Species 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 4
- 241000701027 Human herpesvirus 6 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000341655 Human papillomavirus type 16 Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 229940123776 Immuno-oncology therapy Drugs 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 2
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical group C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical group O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073910P | 2020-09-02 | 2020-09-02 | |
| US63/073,910 | 2020-09-02 | ||
| US202163147473P | 2021-02-09 | 2021-02-09 | |
| US63/147,473 | 2021-02-09 | ||
| PCT/US2021/048771 WO2022051437A2 (en) | 2020-09-02 | 2021-09-01 | Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539370A JP2023539370A (ja) | 2023-09-13 |
| JPWO2022051437A5 true JPWO2022051437A5 (https=) | 2024-09-10 |
| JP2023539370A5 JP2023539370A5 (https=) | 2024-09-10 |
Family
ID=78212608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514418A Pending JP2023539370A (ja) | 2020-09-02 | 2021-09-01 | 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230263879A1 (https=) |
| EP (1) | EP4208192A2 (https=) |
| JP (1) | JP2023539370A (https=) |
| KR (1) | KR20230079066A (https=) |
| CN (1) | CN116406283A (https=) |
| TW (1) | TW202227125A (https=) |
| WO (1) | WO2022051437A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202241466A (zh) * | 2020-12-29 | 2022-11-01 | 美商Ｓｑｚ生物科技公司 | 以經修飾ｐｂｍｃ治療癌症之方法 |
| JP2024536840A (ja) * | 2021-09-26 | 2024-10-08 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－２バリアント及びその融合タンパク質 |
| WO2025140126A1 (en) * | 2023-12-25 | 2025-07-03 | Everest Medicines (China) Co., Ltd. | Therapeutic ly6k mrna vaccine for cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7523203B2 (ja) * | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| US12599656B2 (en) * | 2018-03-12 | 2026-04-14 | Stemcell Technologies Canada Inc. | Methods for treating HPV-associated diseases |
| MX2021006393A (es) * | 2018-11-29 | 2021-10-13 | Univ Texas | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. |
| CA3131701A1 (en) * | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| JP7820663B1 (ja) * | 2024-09-25 | 2026-02-26 | ダイキン工業株式会社 | 設備管理装置、プログラム、設備管理システム |
-
2021
- 2021-09-01 KR KR1020237010604A patent/KR20230079066A/ko active Pending
- 2021-09-01 WO PCT/US2021/048771 patent/WO2022051437A2/en not_active Ceased
- 2021-09-01 US US18/043,613 patent/US20230263879A1/en active Pending
- 2021-09-01 JP JP2023514418A patent/JP2023539370A/ja active Pending
- 2021-09-01 CN CN202180071943.1A patent/CN116406283A/zh active Pending
- 2021-09-01 EP EP21794031.1A patent/EP4208192A2/en active Pending
- 2021-09-02 TW TW110132703A patent/TW202227125A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6109800B2 (ja) | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン | |
| CN103898051B (zh) | 提高免疫反应性的方法 | |
| JP2021517813A5 (https=) | ||
| Matthews et al. | Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation | |
| CN103533955A (zh) | 用于激发t细胞的方法 | |
| JPWO2019178005A5 (https=) | ||
| WO2011052545A1 (ja) | 抗原特異的ｂ細胞集団の製造方法 | |
| JPWO2019178006A5 (https=) | ||
| JP2023539370A (ja) | 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法 | |
| JPWO2022051437A5 (https=) | ||
| CN109796536A (zh) | 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法 | |
| US20130196380A1 (en) | In vitro process for the preparation of antibodies of the igg type | |
| KR100734525B1 (ko) | 인간 및 비근교계 동물에서 세포독성 ｔ 임파구 활성을효과적으로 측정하는 방법 | |
| Lasaro et al. | Potentiating vaccine immunogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system | |
| CN117924437B (zh) | 一种新型冠状病毒重组亚单位抗原及其制备方法和应用 | |
| RU2022132009A (ru) | Комбинированная терапия модифицированными мнпк и иммуноконъюгатом | |
| AU2012202953B2 (en) | HIV vaccine based on targeting maximized Gag and Nef to dendritic cells | |
| CN114075290A (zh) | Cd40靶向结合蛋白、其编码核酸以及用途 | |
| HK40083361A (en) | Combination therapy with modified pbmcs and an immunoconjugate | |
| JPWO2022147026A5 (https=) |